EP 4392413 A1 20240703 - TREATMENT FOR NEUROINFLAMMATORY DISORDERS
Title (en)
TREATMENT FOR NEUROINFLAMMATORY DISORDERS
Title (de)
BEHANDLUNG VON NEUROINFLAMMATORISCHEN ERKRANKUNGEN
Title (fr)
TRAITEMENT DE TROUBLES NEUROINFLAMMATOIRES
Publication
Application
Priority
- IN 202121038491 A 20210825
- IB 2022057951 W 20220825
Abstract (en)
[origin: WO2023026222A1] The present invention relates to the development of therapeutic compound for the treatment of brain psychiatric diseases. Specifically, the present invention provides a NLRP3 inhibitors or its pharmaceutically acceptable salt or suitable composition useful in the treatment of neuroinflammatory disorders or neurodegenerative disorder diseases. These severe and persistent illnesses include Traumatic brain injury (TBI), Amyotrophic lateral sclerosis (ALS), Alzheimer disease (AD), Parkinson's disease (PD), Multiple sclerosis (MS), Huntington disease and other related forms of disorders.
IPC 8 full level
C07D 401/06 (2006.01); A61K 31/40 (2006.01); A61P 25/16 (2006.01); A61P 25/28 (2006.01); A61P 29/00 (2006.01); C07D 205/04 (2006.01); C07D 405/06 (2006.01); C07D 487/04 (2006.01)
CPC (source: EP KR)
A61K 31/18 (2013.01 - KR); A61K 31/341 (2013.01 - KR); A61K 31/381 (2013.01 - KR); A61K 31/40 (2013.01 - EP KR); A61K 31/4164 (2013.01 - KR); A61K 31/426 (2013.01 - KR); A61K 31/4985 (2013.01 - KR); A61P 25/00 (2018.01 - KR); A61P 25/16 (2018.01 - EP KR); A61P 25/28 (2018.01 - EP); A61P 29/00 (2018.01 - EP); C07D 207/08 (2013.01 - EP); C07D 233/64 (2013.01 - EP); C07D 277/16 (2013.01 - EP); C07D 307/64 (2013.01 - EP); C07D 333/34 (2013.01 - EP); C07D 487/04 (2013.01 - EP)
Designated contracting state (EPC)
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated extension state (EPC)
BA ME
Designated validation state (EPC)
KH MA MD TN
DOCDB simple family (publication)
WO 2023026222 A1 20230302; CA 3226855 A1 20230302; CN 117858871 A 20240409; EP 4392413 A1 20240703; KR 20240052009 A 20240422
DOCDB simple family (application)
IB 2022057951 W 20220825; CA 3226855 A 20220825; CN 202280057882 A 20220825; EP 22860750 A 20220825; KR 20247009685 A 20220825